Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

Recruiting

Phase 3

REGN7508 & REGN9933Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

Sponsor:

Regeneron Pharmaceuticals

Code:

NCT07318610

Conditions

Peripheral Artery Disease (PAD)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

REGN7508

REGN9933

Placebo

Rivaroxaban

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-04. This information was provided to ClinicalTrials.gov by Regeneron Pharmaceuticals on 2026-05-22.